Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers co-driven by mutant EGFR containing T790M and MET

Tyrosine kinase inhibitors (TKIs) that target the epidermal growth factor receptor (EGFR) are effective in most NSCLC patients whose tumors harbor activating EGFR kinase domain mutations. Unfortunately, acquired resistance eventually emerges in these chronically treated cancers. Two of the most comm...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Xu, Lu, Kikuchi, Eiki, Xu, Chunxiao, Ebi, Hiromichi, Ercan, Dalia, Cheng, Katherine A., Padera, Robert, Engelman, Jeffrey A., Jänne, Pasi A., Shapiro, Geoffrey I., Shimamura, Takeshi, Wong, Kwok-Kin
Format: Artigo
Sprog:Inglês
Udgivet: 2012
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3389159/
https://ncbi.nlm.nih.gov/pubmed/22552292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-11-3720
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker